AB
LFCR icon

Amalgamated Bank’s Lifecore Biomedical LFCR Stock Holding History

Amalgamated Bank’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-877
Closed -$7K – 2280
2025
Q4 		$7K Buy
877
+140
+19% +$1.04K ﹤0.01% 2580
2025
Q3 		$5K Hold
737
– – ﹤0.01% 2771
2025
Q2 		$6K Hold
737
– – ﹤0.01% 2667
2025
Q1 		$5K Hold
737
– – ﹤0.01% 2667
2024
Q4 		$5K Hold
737
– – ﹤0.01% 2733
2024
Q3 		$4K Hold
737
– – ﹤0.01% 2824
2024
Q2 		$4K Buy
+737
New +$4.37K ﹤0.01% 2860
2023
Q2 		– Sell
-2,713
Closed -$10K – 3082
2023
Q1 		$10K Sell
2,713
-608
-18% -$3.39K ﹤0.01% 2818
2022
Q4 		$22K Hold
3,321
– – ﹤0.01% 2727
2022
Q3 		$30K Hold
3,321
– – ﹤0.01% 2676
2022
Q2 		$33K Buy
3,321
+158
+5% +$1.56K ﹤0.01% 2668
2022
Q1 		$37K Buy
+3,163
New +$35.2K ﹤0.01% 2604

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Bank's LFCR Position: Q1 2026 in Review

Amalgamated Bank sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 877 shares — an estimated $7K sold.

Amalgamated Bank first reported a position in LFCR in Q1 2022 and held it in 12 quarters. The position peaked at $37K in Q1 2022. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • Amalgamated Bank reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 877 Lifecore Biomedical shares in Q1 2026, an estimated $7K.
  • Amalgamated Bank first reported a position in Lifecore Biomedical in Q1 2022 and held it in 12 quarters.
  • Amalgamated Bank's Lifecore Biomedical position peaked at $37K in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.